3/30/23, 1:44 PM 14087

Official reprint from UpToDate®

www.uptodate.com © 2023 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Acute disseminated encephalomyelitis (ADEM) in adults

Author: Amy T Waldman, MD
Section Editors: Francisco González-Scarano, MD, Glenn A Tung, MD, FACR
Deputy Editor: John F Dashe, MD, PhD

All topics are updated as new evidence becomes available and our peer review process is complete.

Literature review current through: Feb 2023. | This topic last updated: Jun 01, 2022.

INTRODUCTION

Acute disseminated encephalomyelitis (ADEM), also known as postinfectious encephalomyelitis,

is an autoimmune demyelinating disease of the central nervous system. Commonly triggered
by viral infections, ADEM is caused by an inflammatory reaction in the brain and spinal cord.
The onset of encephalopathy and multifocal neurologic deficits is acute and often rapidly
progressive.

This topic will review the pathology, epidemiology, clinical features, diagnosis, and treatment of
ADEM in adults. Clinical aspects of ADEM in children are discussed separately. (See "Acute
disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical features, and
diagnosis" and "Acute disseminated encephalomyelitis (ADEM) in children: Treatment and
prognosis".)

PATHOGENESIS

The pathogenesis of ADEM is reviewed here briefly and discussed in greater detail separately.
(See "Acute disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical features,
and diagnosis", section on 'Pathophysiology'.)

Although the pathogenesis is incompletely understood, ADEM appears to be an autoimmune

disorder of the central nervous system that is triggered by an environmental stimulus in
genetically susceptible individuals. One proposed mechanism is that myelin autoantigens such
as myelin basic protein, proteolipid protein, and myelin oligodendrocyte protein share antigenic

https://www.uptodate.com/contents/14087/print 1/33
3/30/23, 1:44 PM 14087

determinants with those of an infecting pathogen. Antiviral antibodies or a cell-mediated

response to the pathogen cross-react with the myelin autoantigens, resulting in ADEM.

PATHOLOGY

Gross neuropathologic brain sections of patients with ADEM often reveal edema [1] (consistent
with observations that ADEM typically improves with glucocorticoid treatment and causes only
minimal neurologic sequelae). However, in other cases the brain may appear normal [2].

The most common histopathologic finding is perivenous infiltration of lymphocytes;

neutrophils, plasma cells, microglial cells, foamy macrophages, and eosinophilic granulocytes
have also been observed [1,3]. Many reports emphasize the finding of perivenous sleeves of
inflammation and demyelination as the pathologic hallmark and predominant lesion of ADEM
[1-7]. In some ADEM cases, these perivenous lesions may eventually coalesce to form confluent
regions of demyelination [7]. This is in contrast with multiple sclerosis, which is typically
associated with multifocal, discrete lesions.

Myelin breakdown products are seen as lipids in macrophages [3]. An inflammatory infiltrate
surrounding blood vessels is often described as cuffing of vessels [4]. Additional features may
include vasculitic-type lesions consisting of inflammation in the vessel walls [1,8], perivascular
necrosis [1,2], lymphocytic infiltration of the meninges [1], and glial nodules in gray matter [1].
Reactive astrocytes are seen in some cases, and gliosis often replaces the inflammatory exudate
[2,4]. Axonal damage has been observed in fatal cases of ADEM [9].

EPIDEMIOLOGY

ADEM is an uncommon illness in adults, thus the precise incidence is unknown [10]. It is
thought to occur more frequently in children. (See "Acute disseminated encephalomyelitis
(ADEM) in children: Pathogenesis, clinical features, and diagnosis", section on 'Epidemiology'.)

ADEM is an expanding phenotype that may overlap with myelin oligodendrocyte glycoprotein
(MOG) antibody-associated disorder (see 'MOG antibody-associated disorder' below). In a
population-based study from Minnesota that evaluated autoimmune and infectious
encephalitis, the prevalence of ADEM without MOG antibodies was 3.3 per 100,000 population,
while the prevalence of MOG-associated demyelination was 1.9 per 100,000 [11].

ADEM has been reported in adults 18 to 82 years of age; the median age ranges from 33 to 41
[12-16].

https://www.uptodate.com/contents/14087/print 2/33
3/30/23, 1:44 PM 14087

● Association with preceding infection – In retrospective studies, ADEM is associated with

a preceding infection in 50 to 75 percent of adult cases [15-18]. As an example, in a study
that included 20 adult patients with an initial diagnosis of ADEM, a preceding infection was
present in 14 (70 percent) [18]. Note that all of these reports are retrospective and limited
by potential referral or recall bias [15-18]. Nevertheless, these data suggest that infection
may be involved in triggering the onset of ADEM.

While ADEM is often preceded by a viral or bacterial infection, an underlying pathogen is

not always identified, and ADEM may follow a nonspecific upper respiratory or
gastrointestinal illness [12,19]. The list of infectious pathogens associated with ADEM
includes rubella, mumps, varicella, measles, smallpox, Epstein-Barr virus, herpes simplex
virus, human herpes virus-6, influenza, HIV, and Mycoplasma pneumoniae [1,2,20-24]. In
addition, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may be
associated; a few case reports have described patients with coronavirus disease 2019
(COVID-19) who had clinical and neuroimaging findings consistent with ADEM. (See
"COVID-19: Neurologic complications and management of neurologic conditions", section
on 'Other acute neurologic manifestations'.)

● Weak association with immunization – Although early reports suggested that a small
minority of ADEM cases followed immunization, subsequent studies have found little or no
association between ADEM and immunization. The frequency of ADEM in the United
States following any vaccine was explored using the Vaccine Safety Datalink, which
captured approximately 64 million doses of 24 different vaccines administered between
2007 and 2012 [25]. There was no increase in the risk of ADEM during the primary
exposure window (5 to 28 days prior to onset) for any vaccine with the possible exception
of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine
(odds ratio [OR] 15.8, 95% CI 1.2-471.6). However, this result was based on only two cases
of ADEM, one of whom received a second vaccine concurrent with Tdap. In addition,
adjustments for multiple comparisons were not performed. Overall, the attributable risk
for ADEM following Tdap was 0.385 per one million doses (95% CI 0.04-1.16).

In early reports, ADEM sometimes occurred after administration of the rabies (Semple)
vaccine, which has not been used in the United States for decades [26]. Typically, adults
and children developed encephalomyelitis 8 to 21 days following the immunization (range
6 to 45 days). Neurologic complications suggestive of ADEM were also reported (rarely)
after vaccines against smallpox, influenza, diphtheria, pertussis, tetanus, measles, rubella,
and polio [1,27-30].

https://www.uptodate.com/contents/14087/print 3/33
3/30/23, 1:44 PM 14087

CLINICAL FEATURES

Classic ADEM — Classic descriptions of ADEM involve a preceding infectious illness in most but
not all cases (see 'Epidemiology' above). After a lag time of a few days to two months (mean 26
days) [13], the typical presentation involves the acute onset of multifocal neurologic symptoms
with encephalopathy, often with rapid deterioration prompting hospitalization [12,13,19,31].
Most patients present with motor deficits; these may involve a single limb or result in
paraparesis (partial paralysis of both legs) or quadriparesis [2,12]. Sensory deficits are frequent,
and brainstem involvement is common, including oculomotor deficits and dysarthria [12].

Additional signs and symptoms may include headache, malaise, meningismus, ataxia, aphasia,
optic neuritis (sometimes bilateral), nystagmus, extrapyramidal movement disorders, urinary
retention, seizures, and increased intracranial pressure [2,12,13,15,16].

In children, where ADEM is more common than in adults, the presence of encephalopathy is
one of the required clinical features for a diagnosis of ADEM, as outlined in the table
( table 1). In adults, the presence of encephalopathy is clinically important, as it helps to
identify individuals who are less likely to have a different disease, such as multiple sclerosis, and
more likely to have ADEM. However, encephalopathy has not always been a required feature for
diagnosis, thus it has been reported in only 20 to 56 percent of adult cases [2,12,15,16]. (See
'Making the diagnosis' below.)

Variant forms — Acute hemorrhagic leukoencephalitis (AHL) is considered a variant type of

ADEM. Some experts recognize additional variants of ADEM, including site-restricted forms such
as postinfectious myelitis or myeloradiculoneuritis, and a form with mixed central and
peripheral nervous system involvement [24,32].

Acute hemorrhagic leukoencephalitis — AHL, also called acute hemorrhagic

encephalomyelitis (AHEM) or acute necrotizing hemorrhagic leukoencephalitis (ANHLE) of
Weston-Hurst, is considered a hyperacute variant of ADEM. Typically, AHL presents after an
infectious illness with meningismus, headache, seizures, multifocal neurologic signs,
asymmetrical neurologic deficits, and rapid progression to coma [1]. Computed tomography
(CT) and magnetic resonance imaging (MRI) of the brain usually reveal hemorrhagic lesions in
the white matter [2]. Additional pathologic features include edema, petechial hemorrhages of
the corona radiata, perivascular hemorrhages, destruction of the vessel walls with fibrin
deposition, and neutrophilic infiltrates [1].

Neuroimaging in one rapidly fatal case did not reveal the presence of hemorrhagic lesions
( figure 1); however, focal hemorrhages were seen on gross sections of the brain at autopsy
https://www.uptodate.com/contents/14087/print 4/33
3/30/23, 1:44 PM 14087

in the white matter of the bilateral posterior frontal and parietal lobes [33].

ADEM with peripheral nervous system involvement — Adults with postinfectious

neurologic syndromes may have clinical or subclinical electrodiagnostic evidence of peripheral
nervous system involvement [24,32]. As an example, one report evaluated 176 adults (median
age 69 years), consisting of one group with purely central nervous system syndromes (30 with
encephalitis, 35 with encephalomyelitis, and 47 with myelitis) and a second group with both
central and peripheral nervous system syndromes (30 patients with
encephalomyeloradiculoneuritis and 34 with myeloradiculoneuritis) [32]. Peripheral nerve
involvement was defined by the presence of electrodiagnostic abnormalities. Clinical symptoms
of peripheral nerve injury, including distal limb paresthesia, perineal anesthesia, and muscle
atrophy, were present in 29 of the 64 patients (46 percent) with electrodiagnostic evidence of
peripheral nerve injury. Patients with peripheral nerve involvement were significantly older and
had a worse prognosis and an elevated risk of relapses compared with those having only
central nervous system syndromes.

EVALUATION AND DIAGNOSIS

When to suspect ADEM — The diagnosis of ADEM should be considered in patients with
unexplained acute encephalopathy and multifocal neurologic signs and symptoms.

Note that ADEM is an evolving topic in both children and adults given the development of cell-
based assays for the detection of anti-myelin oligodendrocyte glycoprotein (MOG)
immunoglobulin G (IgG) antibodies.

Most of the literature describing adults with ADEM was published prior to the systematic
implementation of these assays and widespread testing for anti-MOG antibodies. Thus, it is
challenging to differentiate the clinical, radiographic, and prognostic features of ADEM with and
without MOG-IgG antibodies. However, in patients without MOG-IgG autoantibody, ADEM is
typically monophasic, whereas adults who have an ADEM-like presentation and are seropositive
for MOG-IgG antibodies are more likely to have recurrences [18]. An ADEM-like presentation
may also be the first attack of neuromyelitis optica or, rarely, multiple sclerosis.

Approach to evaluation — The evaluation of a patient with suspected ADEM begins with a
detailed clinical history and examination, which often reveals encephalopathy polyfocal
neurologic symptoms. Patients with suspected ADEM should have the following studies:

● MRI of the brain, cervical and thoracic spine with and without contrast. (See
'Neuroimaging' below.)
https://www.uptodate.com/contents/14087/print 5/33
3/30/23, 1:44 PM 14087

● Lumbar puncture for cerebrospinal fluid (CSF) analysis including (see 'CSF analysis' below):

• Cell counts, protein, glucose, culture (and viral studies if suggested by the clinical
setting and history of outbreaks, such as herpes simplex virus, varicella-zoster virus,
enterovirus, and West Nile virus)
• Qualitative assessment of CSF and serum for oligoclonal immunoglobulin G (IgG)
bands using isoelectric focusing, including IgG synthesis rate and IgG index

● Serologic studies for anti-aquaporin-4 (AQP4) and anti-myelin oligodendrocyte

glycoprotein (MOG) antibodies. (See 'Serum autoantibodies' below.)

Neuroimaging — Patients with suspected ADEM should undergo brain magnetic resonance
imaging (MRI) (without and with contrast), which is the neuroimaging modality of choice. MRI of
the cervical and thoracic spine is also indicated if there are symptoms or signs of myelopathy,
and is helpful in differentiating ADEM from other central nervous system (CNS) demyelinating
disorders such as NMOSD and MS. Therefore, all patients with evidence of CNS demyelination
should have MRI of the cervical and thoracic spine, even in the absence of myelopathy.

● Head CT – Many patients with suspected ADEM or a variant (eg, acute hemorrhagic
encephalomyelitis [AHEM]) present to an emergency room, and an urgent head computed
tomography (CT) scan may be necessary in order to exclude other causes of neurologic
disease (see 'Differential diagnosis' below). However, head CT is usually normal or
nondiagnostic, especially early in the course of ADEM, although some patients may have
scans showing evidence of focal or multifocal white matter damage [34]. Regardless of
head CT findings, MRI is indicated because it is more sensitive for discriminating
demyelinating lesions in the brain and particularly in the spinal cord.

● Brain MRI – Brain lesions on MRI associated with ADEM are typically bilateral and
asymmetric and tend to be poorly marginated [15]. Most patients have multiple lesions in
the deep and subcortical white matter, characteristic of demyelination. On MRI, the lesions
of ADEM are hyperintense on T2-weighted and fluid attenuated inversion recovery (FLAIR)
sequences ( image 1) [34,35] and are usually less conspicuous on unenhanced T1-
weighted sequences [36]. However, large lesions can be slightly hypointense on
unenhanced T1 sequences. There can be considerable heterogeneity: large confluent
lesions ( image 2), single solitary lesions, and multiple small lesions have been
described [5,37]. Lesions may be seen in the periventricular and subcortical white matter,
including corpus callosum and centrum semiovale, as well as in the gray matter, including
the cortex, basal ganglia, and thalamus [12,15,16,38]. Infratentorial lesions in the
brainstem, cerebellum, and spinal cord are common [2,12].

https://www.uptodate.com/contents/14087/print 6/33
3/30/23, 1:44 PM 14087

Brain MRI is almost always abnormal in ADEM. One series reported that brain MRI was
normal in only 3 of 228 children and adults with ADEM; in these three cases, imaging of
the cervical and thoracic spine was performed but results were not reported [16]. Others
have noted that there may be a delay in the appearance of MRI lesions [31,39,40]; in one
report the time lag to MRI lesion appearance was eight weeks from ADEM symptom onset
[39].

● Spinal cord MRI – Lesions in the spinal cord are common in ADEM, although an isolated
spinal cord lesion without supratentorial involvement is rare [35]. Both long and short
segment cord lesions have been reported, but large confluent intramedullary lesions that
extend over multiple segments are more common [41], particularly with MOG antibody-
associated ADEM.

● Enhancing lesions – Gadolinium enhancement of MRI lesions in ADEM is variable.

Enhancing and nonenhancing lesions may appear together in the same scan [2,12,31].
Even though ADEM is usually a monophasic illness, repeat imaging early in the disease
course has shown fluctuation in the presence of both enhancing and nonenhancing
lesions [12], especially in MOG-associated demyelination. New asymptomatic lesions may
appear while others seemingly resolve [2].

● Diffusion MRI – With diffusion-weighted MRI imaging (DWI), lesions associated with
ADEM show restricted diffusion (ie, decreased apparent diffusion coefficient [ADC] values)
in the acute stage, defined as within seven days from symptom onset, whereas increased
diffusivity and normalization of the ADC is seen within a few weeks after the initial
presentation [2,38].

● Resolution of MRI abnormalities – Many MRI lesions resolve within 18 months [2],
although some patients have residual lesions on follow-up imaging [31].

CSF analysis — Lumbar puncture for CSF analysis in suspected ADEM is performed to obtain
evidence of inflammation and differentiate ADEM from other disorders (such as multiple
sclerosis) while concurrently ruling out an infection [42].

● Typical findings – CSF findings in ADEM are variable; while CSF can be normal,
abnormalities are present in 50 to 80 percent of patients [12,15,16,19,24]. Typical
abnormalities in ADEM are nonspecific and include a lymphocytic pleocytosis, usually with
a CSF white blood cell count <100 cells/mL, and a mildly elevated CSF protein, usually <70
mg/dL, although higher counts and levels have been reported [2,5,12,19].

https://www.uptodate.com/contents/14087/print 7/33
3/30/23, 1:44 PM 14087

● Oligoclonal bands – Oligoclonal bands (OCBs) have been reported in 6 to 65 percent of

adult patients with ADEM [12,13,15,16]; in a study that included 102 adult patients with
ADEM who had lumbar puncture performed, OCBs were present in 29 percent [16].
However, other reports suggest that OCBs are rarely found in the CSF children who are
diagnosed according to consensus criteria for childhood ADEM ( table 1) [41]. Rather,
the presence of OCBs in children and adolescents is associated with the evolution to
multiple sclerosis [43]. Positivity for anti-MOG-IgG antibody rarely occurs in patients with
OCBs; thus, both tests are useful in differentiating a MOG antibody-associated disorder
with an ADEM phenotype from ADEM as a first attack of MS.

Serum autoantibodies — Testing for the MOG-IgG autoantibody and the AQP4-IgG serum
autoantibody is indicated for patients presenting with suspected ADEM.

● The anti-MOG-IgG antibody is a marker of MOG antibody-associated disorder, a

demyelinating disorder characterized by a variety of manifestations that include ADEM,
relapsing and bilateral optic neuritis, transverse myelitis, and brainstem encephalitis.
Therefore, MOG antibody-associated disorder is a potential cause of ADEM and other CNS
demyelinating disorders that may be considered in the differential diagnosis of ADEM.
Patients with ADEM who are positive for MOG antibody meet criteria for MOG antibody-
associated disorder [18]. Among young patients with a demyelinating syndrome who go
on to develop MS, positive anti-MOG antibody serology is uncommon [44]. (See 'MOG
antibody-associated disorder' below.)

Although data are limited, one study found that the frequency of MOG antibody
seropositivity among a cohort of 20 adult patients with ADEM was 60 percent [45]. In
children with ADEM, seropositivity for MOG antibodies is found in 33 to 66 percent of
cases [42,44,45].

● The anti-AQP4-IgG antibody is a specific biomarker for neuromyelitis optica spectrum

disorder (NMOSD). Patients with cerebral lesions, optic neuritis, or transverse myelitis who
are seropositive for anti-AQP4 antibodies fulfill criteria for NMOSD [42]. (See
'Neuromyelitis optica spectrum disorder' below.)

Other studies — Ancillary tests, including evoked potentials and electroencephalogram (EEG),
have been studied in ADEM, but the findings are usually nonspecific. Visual evoked and
somatosensory evoked potentials may be abnormal depending on the localization of CNS
lesions; however, these studies do not often contribute to the diagnosis.

The utility of EEG is controversial; typically, the EEG shows bilateral slow activity, which is
nonspecific and nonlocalizing. Given this, some authors do not feel it contributes to the
https://www.uptodate.com/contents/14087/print 8/33
3/30/23, 1:44 PM 14087

diagnosis [2], whereas others argue that the presence of focal slowing or epileptiform
discharges is useful in documenting central nervous system involvement, especially if the MRI
and cerebrospinal fluid findings are normal [19].

Making the diagnosis — The key clinical features that distinguish ADEM from other disorders
are the acute and rapid progression of encephalopathy and multifocal neurologic findings.
There are no specific biomarkers or confirmatory tests to establish the diagnosis of ADEM. The
presence of antibodies to MOG-IgG1 would be classified as MOG-associated demyelination.

● Supportive features – The diagnosis of ADEM is supported by the presence of one or

more supratentorial or infratentorial demyelinating lesions on brain MRI and the absence
of destructive "black hole" lesions on T1-weighted MRI, which suggest prior episodes of
inflammation or demyelination as seen in multiple sclerosis [12]. A preceding infection
and abnormal CSF (a mild lymphocytic pleocytosis and a mildly elevated protein) are
suggestive of ADEM but not required for the diagnosis.

● Diagnosis of exclusion – Given the lack of a specific diagnostic test, ADEM is considered a
diagnosis of exclusion, and other CNS demyelinating and inflammatory syndromes must
be ruled out, particularly MOG antibody-associated disorder and multiple sclerosis [41].
However, diagnostic certainty may be delayed. The evaluation for MOG and AQP4
autoantibodies typically requires send-out laboratory testing and is often pending during
a patient's initial hospitalization and treatment. Similarly, the analysis for CSF-specific
OCBs, which helps distinguish ADEM from a first attack of multiple sclerosis (MS), is a
send-out test as well. (See 'Approach to evaluation' above and 'Differential diagnosis'
below.)

● Diagnostic criteria – Diagnostic criteria for ADEM have been proposed for children, as
listed in the table ( table 1) [46,47]. The two major features required for the diagnosis of
ADEM in children are multifocal central nervous system involvement and encephalopathy.
(See "Acute disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical
features, and diagnosis", section on 'Diagnostic criteria'.)

A consensus set of diagnostic criteria for ADEM has not been established for adults.
However, some investigators have proposed that certain criteria may be used to
distinguish patients with ADEM from those with multiple sclerosis (see 'Multiple sclerosis'
below), including two of the following [13]:

• Presence of symptoms that are atypical for multiple sclerosis such as encephalopathy,
defined as an alteration in consciousness (eg, stupor, lethargy or behavioral change)
that cannot be explained by fever, systemic illness, or postictal symptoms
https://www.uptodate.com/contents/14087/print 9/33
3/30/23, 1:44 PM 14087

• Gray matter involvement on brain MRI

• Absence of OCBs in the CSF

The utility of the third criterion (absence of oligoclonal bands) is questionable since
oligoclonal bands in the CSF are present in some adult patients with ADEM. (See 'CSF
analysis' above.)

DIFFERENTIAL DIAGNOSIS

The most challenging aspect of the diagnostic process is differentiating ADEM from myelin
oligodendrocyte glycoprotein (MOG) antibody-associated disorder, neuromyelitis optica
spectrum disorder (NMOSD), or a first attack of multiple sclerosis.

Other entities to be considered in the differential diagnosis of ADEM include infectious

meningoencephalitis, neurologic sarcoidosis, vasculitis, progressive multifocal
leukoencephalopathy, and Behçet syndrome.

MOG antibody-associated disorder — IgG serum antibodies directed against MOG denote a
separate disease entity termed MOG antibody-associated disorder [48]. The disorder is
characterized by a variety of manifestations related to central nervous system demyelination
that include ADEM and other syndromes, such as relapsing and bilateral optic neuritis,
transverse myelitis, and brainstem encephalitis.

Proposed diagnostic criteria for MOG antibody-associated disorder require serum positivity for
MOG-immunoglobulin G (IgG), a clinical presentation consistent with central nervous system
demyelination (ie, ADEM, optic neuritis, transverse myelitis, a brain or brainstem demyelinating
syndrome, or any combination of these), and exclusion of an alternative diagnosis [18]. In the
absence of serum, positivity for MOG-IgG in the CSF allows fulfillment of the criteria. A transient
seropositivity may indicate a lower risk of relapse.

Multiple sclerosis — Multiple sclerosis (MS) is a chronic, autoimmune, demyelinating disease

characterized by recurrent attacks separated in time and space. (See "Manifestations of multiple
sclerosis in adults" and "Evaluation and diagnosis of multiple sclerosis in adults".)

Certain clinical features may be helpful in supporting the diagnosis of ADEM or MS [12,13].
However, there is substantial overlap:

● ADEM typically follows a prodromal viral illness, while MS may not.

● ADEM may present with fever and stiff neck, which is unusual in MS.

https://www.uptodate.com/contents/14087/print 10/33
3/30/23, 1:44 PM 14087

● ADEM usually produces a widespread central nervous system disturbance, often with
impaired consciousness and/or encephalopathy, while MS typically is monosymptomatic
(eg, optic neuritis or a subacute myelopathy) and has a relapsing-remitting course. MS
flares do not typically cause encephalopathy.
● Ataxia is a common presenting feature of ADEM but is less commonly seen as a
presenting feature in MS.

Brain magnetic resonance imaging (MRI) features may also be helpful in distinguishing ADEM
from MS (see 'Neuroimaging' above), although complete differentiation is not possible based
on a single study:

● ADEM usually has more MRI lesions than early MS, with larger bilateral but asymmetric
white matter abnormalities.
● Lesions tend to be poorly defined in ADEM and have better defined margins in MS.
● The presence of brain lesions of approximately the same age on MRI is most consistent
with ADEM, while the presence of brain lesions of different ages and/or the presence of
black holes (hypointense T1-weighted lesions) suggests MS.
● Periventricular lesions are less common in ADEM than MS.

In a retrospective series of 54 patients evaluated for acute demyelinating disease, the final
diagnosis was monophasic ADEM in 35 and MS in 19 [13]. Atypical symptoms for MS (ie,
encephalopathy, aphasia, hemiplegia, paraplegia, tetraplegia, seizure, vomiting, or bilateral
optic neuritis) were more common in the ADEM group compared with the MS group (74 and 42
percent, respectively), and gray matter (cortex or basal ganglia) involvement on brain MRI was
more frequent in the ADEM group (60 versus 11 percent). By contrast, corpus callosum
involvement was less frequent in the ADEM group compared with the MS group (23 percent
versus 79 percent), as were oligoclonal bands in the cerebrospinal fluid (20 percent versus 84
percent).

Neuromyelitis optica spectrum disorder — Neuromyelitis optica spectrum disorder (NMOSD),

discussed in detail elsewhere (see "Neuromyelitis optica spectrum disorders (NMOSD): Clinical
features and diagnosis"), is an inflammatory disorder of the central nervous system
characterized by severe, immune-mediated demyelination and axonal damage predominantly
targeting the optic nerves and spinal cord, but also the brain and brainstem. NMOSD is
distinguished based upon the presence of the disease-specific aquaporin-4 (AQP4) antibody,
which plays a direct role in the pathogenesis of NMOSD. (See "Neuromyelitis optica spectrum
disorders (NMOSD): Clinical features and diagnosis", section on 'History' and "Neuromyelitis
optica spectrum disorders (NMOSD): Clinical features and diagnosis", section on
'Pathogenesis'.)
https://www.uptodate.com/contents/14087/print 11/33
3/30/23, 1:44 PM 14087

Clinical features of NMOSD overlap with other neuroinflammatory disorders, such as MS and
MOG antibody-associated disorder. Hallmark features of NMOSD include acute attacks
characterized by bilateral or rapidly sequential optic neuritis (leading to visual loss), acute
transverse myelitis (often causing limb weakness and bladder dysfunction), and the area
postrema syndrome (with intractable hiccups or nausea and vomiting). Other suggestive
symptoms include episodes of excessive daytime somnolence or narcolepsy, reversible
posterior leukoencephalopathy syndrome, neuroendocrine disorders, and (in children) seizures.
While no clinical features are disease-specific, some are highly characteristic. NMOSD has a
relapsing course in 90 percent or more of cases. (See "Neuromyelitis optica spectrum disorders
(NMOSD): Clinical features and diagnosis", section on 'Clinical features'.)

Diagnostic criteria for NMOSD ( table 2) require the presence of at least one core clinical
characteristic (eg, optic neuritis, acute myelitis, area postrema syndrome), a positive test for
AQP4-IgG, and exclusion of alternative diagnoses. The diagnostic criteria are more exacting in
the setting of negative or unknown AQP4-IgG antibody status ( table 2). (See "Neuromyelitis
optica spectrum disorders (NMOSD): Clinical features and diagnosis", section on 'Evaluation and
diagnosis'.)

Infectious meningoencephalitis — Infectious meningoencephalitis should be included in the

differential diagnosis of ADEM, especially in patients presenting with fever, headache, and
meningismus. Acute viral encephalitis typically affects the gray matter and can present with
seizures, as seen in herpes simplex virus (HSV) infections. The most important diagnostic
consideration in patients with encephalitis is HSV since delay in treatment can affect morbidity
and mortality. (See "Viral encephalitis in adults".)

CSF examination of patients with suspected meningitis or encephalitis is essential for diagnosis.
In the appropriate setting, a lymphocytic predominance is suggestive of a viral rather than a
bacterial etiology; the presence of red blood cells in the absence of a traumatic tap is
suggestive of HSV or other necrotizing viral encephalitides. Diagnostic CSF polymerase chain
reaction (PCR) for HSV-1 and immunoglobulin M (IgM) antibody in CSF and serum for West Nile
virus are recommended for patients with encephalitis. Testing for other viral pathogens will
depend on travel or exposure history to insects and animals. Serologic testing for West Nile
virus, mumps, and Epstein-Barr virus can also be considered in the appropriate clinical setting.
(See "Viral encephalitis in adults", section on 'Diagnosis'.)

Sarcoidosis — Sarcoidosis is an autoimmune disease that may involve any organ system, most
commonly the lungs and skin. The pathologic finding is non-caseating granulomas. Neurologic
complications occur in approximately 5 percent of patients with sarcoidosis. (See "Neurologic
sarcoidosis".)
https://www.uptodate.com/contents/14087/print 12/33
3/30/23, 1:44 PM 14087

The most common features of neurologic sarcoidosis are cranial mononeuropathy,

neuroendocrine dysfunction, a focal or multifocal encephalopathy, myelopathy, hydrocephalus,
aseptic meningitis, peripheral neuropathy, or myopathy (see "Neurologic sarcoidosis", section
on 'Clinical features'). Parenchymal involvement mimicking inflammatory disorders such as
ADEM or multiple sclerosis may also be seen. Sarcoidosis is more commonly a chronic recurrent
disease and less likely to be monophasic. However, patients presenting with neurosarcoidosis
may have no systemic features of the disease and thus present a diagnostic challenge. Thus,
the diagnostic evaluation requires distinguishing neurosarcoidosis from a variety of other
inflammatory and infectious conditions. (See "Neurologic sarcoidosis", section on 'Differential
diagnosis'.)

A thorough evaluation for systemic sarcoidosis (eg, chest imaging, skin evaluation) can expedite
the evaluation by providing tissue that is accessible for biopsy. In the absence of systemic
sarcoidosis, testing that may be helpful includes contrast-enhanced MRI of the affected area
(brain and/or spinal cord), cerebrospinal fluid evaluation (see "Neurologic sarcoidosis", section
on 'Lumbar puncture') and serum angiotensin converting enzyme level. None of these tests
have perfect sensitivity and specificity. (See "Neurologic sarcoidosis", section on 'Clinical
evaluation' and "Neurologic sarcoidosis", section on 'Neurodiagnostic testing'.)

Vasculitis — Vasculitis may mimic ADEM, as it can present with evolving multifocal deficits
secondary to deep brain infarcts (see "Overview of and approach to the vasculitides in adults").
Headaches, seizures, and cognitive, mood, or behavioral changes can occur in ADEM but are
more common in some vasculitides. Magnetic resonance angiography (MRA) may reveal
abnormal vessels, but is often nondiagnostic. While conventional angiography is perhaps more
sensitive in the diagnosis of vasculitis, it may still be negative; leptomeningeal biopsy may be
necessary to increase the diagnostic yield. Vasculitis secondary to systemic autoimmune
diseases can be diagnosed by the appropriate rheumatologic serologies and other systemic
manifestations.

Patients with primary angiitis of the central nervous system (PACNS) may present with altered
mental status, followed by the accrual of multifocal CNS deficits (see "Primary angiitis of the
central nervous system in adults", section on 'Clinical manifestations'). Signs and symptoms of
systemic vasculitis, such as peripheral neuropathy, fever, weight loss, or rash, are usually
absent. CSF pleocytosis with elevated protein is typical but not specific for PACNS. MRI of the
brain commonly shows multiple infarcts in multiple vascular territories, and often in areas of
the brain not affected by more common causes of stroke (such as the corpus callosum).
However, these findings are not specific for PACNS. Cerebral angiography findings that are
compatible with (but not diagnostic of) PACNS include beading, circumferential or eccentric

https://www.uptodate.com/contents/14087/print 13/33
3/30/23, 1:44 PM 14087

luminal narrowing, occlusions of one or more arteries, and/or an avascular mass effect, but the
sensitivity and specificity of angiography for the diagnosis are suboptimal. The gold standard
for the diagnosis of PACNS is histopathology of the leptomeninges and underlying cortex.
However, brain/leptomeningeal biopsies are only approximately 75 percent sensitive for the
diagnosis of PACNS. (See "Primary angiitis of the central nervous system in adults", section on
'Establishing the diagnosis'.)

Progressive multifocal leukoencephalopathy — Progressive multifocal leukoencephalopathy

(PML) is a demyelinating inflammatory disease of the brain caused by the JC virus. PML occurs
almost exclusively in immunosuppressed individuals. (See "Progressive multifocal
leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis", section on
'Epidemiology'.)

As the name implies, classic PML is progressive, multifocal, and involves the white matter.
Similar to ADEM, patients with PML may present with multifocal neurologic deficits, including
motor weakness, visual changes, and cognitive impairment. Its onset may be less acutely
fulminant than ADEM, but it progresses rapidly over several months, usually resulting in severe
disability and death. The typical appearance of PML on neuroimaging studies consists of
symmetric or asymmetric multifocal areas of white matter demyelination that do not conform
to cerebrovascular territories and exhibit neither mass effect nor contrast enhancement. (See
"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and
diagnosis", section on 'Clinical forms'.)

The diagnosis of PML is confirmed by PCR detection of JC virus DNA in the CSF in patients with
appropriate neurologic and neuroradiologic features, or less commonly by brain biopsy. (See
"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and
diagnosis", section on 'Diagnosis'.)

Behçet syndrome — Behçet syndrome is a rare condition characterized by recurrent oral

aphthae and any of several systemic manifestations, including genital aphthae, ocular disease,
skin lesions, gastrointestinal disease, neurologic disease, vascular disease, and arthritis. Most
clinical manifestations of Behçet syndrome are believed to be due to vasculitis. Behçet
syndrome is more common (and often more severe) along the ancient Silk Road, which extends
from eastern Asia to the Mediterranean; the prevalence is much lower in North America and
northern Europe. It typically affects young adults 20 to 40 years of age. (See "Clinical
manifestations and diagnosis of Behçet syndrome", section on 'Epidemiology'.).

Neurologic disease occurs in less than one-fifth of patients with Behçet syndrome and is
observed more frequently in men than women. Neurologic involvement may mimic

https://www.uptodate.com/contents/14087/print 14/33
3/30/23, 1:44 PM 14087

demyelinating disease. There may be acute or chronic recurrent meningitis,

meningoencephalitis with changes in mental status, parenchymal involvement with multifocal
lesions in the gray and white matter, or brainstem and cranial nerve involvement. (See "Clinical
manifestations and diagnosis of Behçet syndrome", section on 'Neurologic disease'.)

There are no pathognomonic laboratory findings in Behçet syndrome; the diagnosis is made
based on the clinical findings. Nonspecific elevation of acute phase reactants is often seen. CSF
analysis typically reveals a pleocytosis; chronic counts <60 cells/mL are most common, but
counts >500 cells/mL may be seen in the acute meningitis presentation of Behçet syndrome.
Diagnostic criteria require the presence of recurrent oral aphthae (three times in one year) plus
two more manifestations that can include recurrent genital ulcerations, eye lesions, skin
lesions, or a positive pathergy test. (See "Clinical manifestations and diagnosis of Behçet
syndrome", section on 'Diagnosis'.)

TREATMENT

Immune suppression is the mainstay of treatment for ADEM.

Initial therapy — We recommend initial therapy with high-dose glucocorticoids for adults with
ADEM [49]. Glucocorticoids may be started at the time of the patient's presentation and can be
used concurrently with acyclovir and antibiotics. A typical regimen is intravenous
methylprednisolone, 1000 mg daily for three to five days, followed by an oral glucocorticoid
taper of variable duration.

Efficacy of glucocorticoids — In uncontrolled observational studies, treatment of adults with

ADEM using intravenous methylprednisolone (1000 mg daily for three to five days), followed by
an oral glucocorticoid taper over four to six weeks, was associated with substantial clinical
improvement in a majority of patients [12,32]. Similar data suggesting benefit of intravenous
glucocorticoids for ADEM have been reported in children. (See "Acute disseminated
encephalomyelitis (ADEM) in children: Treatment and prognosis", section on 'Glucocorticoids'.)

Anecdotally, the need for glucocorticoid tapering is uncertain; shorter duration tapering is often
used in clinical practice.

Empiric antibiotics for select patients — Some adults with ADEM present with fever,
meningeal signs, acute encephalopathy, and evidence of inflammation in blood and
cerebrospinal fluid. For such patients, empiric treatment with acyclovir should be started if the
patient has encephalitis without apparent explanation and continued until an infectious
etiology is excluded. (See "Viral encephalitis in adults", section on 'Empiric therapy'.).
https://www.uptodate.com/contents/14087/print 15/33
3/30/23, 1:44 PM 14087

Empiric antibiotics for possible bacterial meningitis are not necessary unless the cerebrospinal
fluid findings suggest a bacterial inflammatory profile. (see "Clinical features and diagnosis of
acute bacterial meningitis in adults", section on 'Cerebrospinal fluid analysis').

Inadequate response to initial therapy — For patients with ADEM who have a poor response
to glucocorticoids, therapeutic options include intravenous immune globulin (IVIG) or plasma
exchange. In addition, alternate diagnoses should be explored for patients who have suspected
ADEM that does not respond well to glucocorticoids.

Intravenous immune globulin — IVIG can be used if the response to a five-day course of
glucocorticoids is poor. In one report, three patients with classic ADEM and poor response to
glucocorticoids were treated with IVIG (0.4 g/kg intravenously daily for five days) and
demonstrated improvement in the first week of therapy, reaching maximum benefit within the
first three weeks [50]. (See "Overview of intravenous immune globulin (IVIG) therapy".)

Among patients with ADEM who have electrodiagnostic or clinical evidence of peripheral
nervous system involvement (see 'ADEM with peripheral nervous system involvement' above), a
prospective uncontrolled study found that IVIG treatment was associated with a favorable
outcome in approximately 50 percent of patients for whom high-dose glucocorticoids were
ineffective [32].

Plasma exchange — Plasma exchange has also been used for ADEM in adults when
glucocorticoids are ineffective, but data are limited [51]. One retrospective cohort study of
plasma exchange for all demyelinating diseases, including 10 patients with ADEM, showed that
male sex, preserved reflexes on examination, and early initiation of therapy were associated
with improved outcomes [49].

Plasma exchange for ADEM is generally given as five to seven exchanges over 10 to 14 days.
One reasonable regimen is six exchanges, one every other day, with each exchange consisting
of 1 to 1.5 plasma volumes. (See "Therapeutic apheresis (plasma exchange or cytapheresis):
Indications and technology".)

Other options — Cyclophosphamide, 1 gram given intravenously, has also been used for
patients when the response to glucocorticoids is poor. Repeat dosing may be necessary to
achieve maximum benefit [12].

Management of malignant edema — In some cases, fulminant ADEM or acute hemorrhagic

leukoencephalitis may progress to develop malignant, space-occupying brain edema with
increased intracranial pressure and brain tissue shifts or herniation [52]. This process can lead
to neurologic deterioration with signs that typically include decreased arousal, pupillary
https://www.uptodate.com/contents/14087/print 16/33
3/30/23, 1:44 PM 14087

changes, and worsening of motor responses. These neurologic signs are indicators of the need
to intervene urgently with measures to treat brain edema.

Standard medical therapy for worsening edema involves close monitoring for neurologic
complications; and interventions to reduce intracerebral pressure such as elevation of the head
of the bed, osmotic therapy, brief periods of hyperventilation as needed, and hemicraniectomy
for patients with life-threatening cerebral edema [53,54]. (See "Evaluation and management of
elevated intracranial pressure in adults".)

Monitoring — For patients with ADEM who remain asymptomatic, an annual brain MRI with
and without gadolinium for several years is suggested to monitor for the development of new
lesions and possible multiple sclerosis.

For patients with detectable anti-myelin oligodendrocyte glycoprotein (MOG) antibody titers at
presentation with ADEM, repeat testing should be performed every six months for at least one
year. Patients with persistently high titers should be closely observed clinically and have repeat
imaging every 6 to 12 months. Persistent seropositivity for anti-MOG antibodies is associated
with an increased risk for relapse, as discussed in the section that follows.

PROGNOSIS

Compared with ADEM in children, the available studies suggest that the clinical course is more
severe and outcome is less favorable in adults with ADEM [15,55]. Nevertheless, most patients
improve with treatment, and spontaneous recovery has occurred in patients with mild
symptoms [50]. Complete recovery has been reported in 10 to 46 percent of adults [12,15,19].
Cognitive impairment, mostly affecting attention and concentration, has persisted in some.

● Mortality – ADEM may be fatal especially in fulminant cases, with mortality rates of 4 to
12 percent reported in larger modern series [12,15,50]. In one report of 20 patients with
ADEM admitted to the intensive care unit, the mortality rate was 25 percent [14]. Thirty-
five percent of survivors in this series were left with permanent disability.

● Relapses – Although traditionally considered to be a monophasic illness, up to one-

quarter of adults with ADEM experience at least one relapse [16,56]. Of note, patients in
these studies were not routinely tested for the presence of myelin oligodendrocyte
glycoprotein (MOG) antibodies, which is associated with a higher likelihood of relapses.
Nevertheless, ADEM has recurred in cases without MOG antibodies. In such recurrences,
the symptoms often localize to the site of the central nervous system that was originally
affected. In fact, new clinical symptoms may localize to a previously silent lesion on
https://www.uptodate.com/contents/14087/print 17/33
3/30/23, 1:44 PM 14087

neuroimaging [5]. Relapses may also present as cognitive difficulties or neuropsychiatric

disease, such as depression or psychosis [57].

Persistent seropositivity for anti-MOG antibodies is associated with an increased risk for
relapse [18,48].

Recurrent ADEM frequently responds to glucocorticoid treatment. Relapsing disease

associated with MOG antibodies may require other immune suppression. (See 'Efficacy of
glucocorticoids' above.)

The International Pediatric MS Study Group (IPMSSG) have defined ADEM by the
simultaneous presence of polyfocal neurologic symptoms and encephalopathy [46,47]. In
contrast to pediatric ADEM, the presence of encephalopathy may not distinguish those
adults likely to have monophasic disease. In two adult cohorts, encephalopathy was
present in approximately half of patients with an initial diagnosis of ADEM, and among
patients who were longitudinally confirmed to have a monophasic course, only 36 to 58
percent had encephalopathy as part of their initial attack [15,16].

● Progression to multiple sclerosis – In patients initially diagnosed with ADEM, relapses

that involve a new central nervous system territory should raise suspicion for MOG
antibody-associated disorder or multiple sclerosis (see 'Multiple sclerosis' above). In one
study of adults with an ADEM-like first attack, 35 percent were confirmed to have multiple
sclerosis over an average of 38 months, with most patients developing new attacks within
one year [12].

SOCIETY GUIDELINE LINKS

Links to society and government-sponsored guidelines from selected countries and regions
around the world are provided separately. (See "Society guideline links: Multiple sclerosis and
related disorders".)

SUMMARY AND RECOMMENDATIONS

● Acute disseminated encephalomyelitis (ADEM) is an autoimmune demyelinating disease of

the central nervous system that typically follows an infection. Histopathology of ADEM
reveals perivascular infiltration of lymphocytes. Perivenous demyelination is a frequent
finding. (See 'Pathogenesis' above and 'Pathology' above.)

https://www.uptodate.com/contents/14087/print 18/33
3/30/23, 1:44 PM 14087

● ADEM is an uncommon disease, but the precise incidence in adults is unknown. ADEM is
thought to be more frequent in children than adults. (See 'Epidemiology' above.)

● ADEM typically presents after a preceding illness with multifocal neurologic signs and
encephalopathy (altered mental status). Other common neurologic manifestations include
motor, sensory, cranial nerve, and brainstem deficits as well as nonspecific symptoms
such as headache and malaise. (See 'Clinical features' above.)

● Acute hemorrhagic leukoencephalitis is a hyperacute variant of ADEM that may be fatal.

Petechial or gross hemorrhages may occur ( figure 1). (See 'Acute hemorrhagic
leukoencephalitis' above.)

● The evaluation for ADEM requires neuroimaging, preferably with magnetic resonance
imaging (MRI), lumbar puncture for cerebrospinal fluid (CSF) analysis, and serum
autoantibody testing for anti-myelin oligodendrocyte glycoprotein (MOG) and anti-
aquaporin-4 (AQP4), preferably with a cell-based assay. (See 'Evaluation and diagnosis'
above.)

• On MRI, lesions associated with ADEM are typically bilateral but may be asymmetric
and tend to be poorly marginated. Most patients have multiple lesions in the deep and
subcortical white matter. The lesions are hyperintense on T2-weighted and fluid-
attenuated inversion recover (FLAIR) sequences ( image 1); on unenhanced T1-
weighted sequences, small lesions are usually inconspicuous while large lesions are
mildly hypointense. Gadolinium enhancement is variable. (See 'Neuroimaging' above.)

• Lumbar puncture may be normal, or may reveal a lymphocytic pleocytosis or elevated

protein. The presence of oligoclonal bands in the CSF (but not serum) or elevated
immunoglobulin G (IgG) index is more common in multiple sclerosis but can also be
seen in ADEM. (See 'CSF analysis' above.)

• Anti-MOG antibodies are indicative of MOG antibody-associated disorder, which can

manifest as ADEM. Anti-AQP4 antibodies are indicative of NMOSD. (See 'Serum
autoantibodies' above.)

● The diagnosis of ADEM is considered in patients with encephalopathy and unexplained

acute multifocal neurologic signs and symptoms. The diagnosis is supported by the
presence of one or more supratentorial or infratentorial demyelinating lesions on brain
MRI and the absence of destructive "black hole" lesions on T1-weighted MRI. A preceding
infection and abnormal CSF are suggestive of ADEM, but not required for the diagnosis.

https://www.uptodate.com/contents/14087/print 19/33
3/30/23, 1:44 PM 14087

There are no specific biomarkers to establish the diagnosis. (See 'Making the diagnosis'
above.)

● In adults, ADEM is difficult to distinguish from multiple sclerosis. Other entities to be

considered in the differential of ADEM include infectious meningoencephalitis, neurologic
sarcoidosis, vasculitis, progressive multifocal leukoencephalopathy, and Behçet syndrome.
(See 'Differential diagnosis' above.)

● Immune suppression is the mainstay of treatment for ADEM. For adults with ADEM, we
recommend initial therapy with high-dose glucocorticoids (Grade 1C). Reasonable
regimens include intravenous methylprednisolone 1000 mg daily for three to five days. For
patients with suspected ADEM who present with symptoms suggestive of encephalitis, it is
reasonable to treat empirically with acyclovir until an infectious etiology is excluded. For
those who have an insufficient response to intravenous glucocorticoid treatment,
therapeutic options include intravenous immune globulin (IVIG) treatment, 0.4 g/kg daily
for five days, or plasma exchange. (See 'Treatment' above.)

● Most patients with ADEM improve with treatment, but complete recovery occurs in only 10
to 46 percent of adult patients, with motor deficits and/or cognitive impairment often
persisting in the remainder. In fulminant cases, death may result. Relapses, though
unusual, have occurred. Relapses that involve a different region of the central nervous
system should raise suspicion for multiple sclerosis. (See 'Prognosis' above.)

ACKNOWLEDGMENT

The editorial staff at UpToDate acknowledge Dina Jacobs, MD, who contributed to earlier
versions of this topic review.

Use of UpToDate is subject to the Terms of Use.

REFERENCES

1. Hart MN, Earle KM. Haemorrhagic and perivenous encephalitis: a clinical-pathological

review of 38 cases. J Neurol Neurosurg Psychiatry 1975; 38:585.

2. van der Knaap MS, Valk J. Acute disseminated encephalomyelitis and acute hemorrhagic en
cephalomyelitis. In: Magnetic Resonance of Myelination and Myelin Disorders, 3rd edition,
Springer, New York 2005. p.604.

https://www.uptodate.com/contents/14087/print 20/33
3/30/23, 1:44 PM 14087

3. Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: intermediate entity
between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31
patients. Ann Neurol 1993; 33:18.
4. Mader I, Stock KW, Ettlin T, Probst A. Acute disseminated encephalomyelitis: MR and CT
features. AJNR Am J Neuroradiol 1996; 17:104.

5. Cohen O, Steiner-Birmanns B, Biran I, et al. Recurrence of acute disseminated

encephalomyelitis at the previously affected brain site. Arch Neurol 2001; 58:797.

6. VAN BOGAERT L. Post-infectious encephalomyelitis and multiple sclerosis; the significance

of perivenous encephalomyelitis. J Neuropathol Exp Neurol 1950; 9:219.
7. Young NP, Weinshenker BG, Parisi JE, et al. Perivenous demyelination: association with
clinically defined acute disseminated encephalomyelitis and comparison with
pathologically confirmed multiple sclerosis. Brain 2010; 133:333.
8. Hawkins CP, Mackenzie F, Tofts P, et al. Patterns of blood-brain barrier breakdown in
inflammatory demyelination. Brain 1991; 114 ( Pt 2):801.
9. Ghosh N, DeLuca GC, Esiri MM. Evidence of axonal damage in human acute demyelinating
diseases. J Neurol Sci 2004; 222:29.
10. Garg RK. Acute disseminated encephalomyelitis. Postgrad Med J 2003; 79:11.
11. Dubey D, Pittock SJ, Kelly CR, et al. Autoimmune encephalitis epidemiology and a
comparison to infectious encephalitis. Ann Neurol 2018; 83:166.
12. Schwarz S, Mohr A, Knauth M, et al. Acute disseminated encephalomyelitis: a follow-up
study of 40 adult patients. Neurology 2001; 56:1313.

13. de Seze J, Debouverie M, Zephir H, et al. Acute fulminant demyelinating disease: a

descriptive study of 60 patients. Arch Neurol 2007; 64:1426.
14. Sonneville R, Demeret S, Klein I, et al. Acute disseminated encephalomyelitisin the intensive
care unit:clinical features and outcome of 20 adults. Intensive Care Med 2008; 34:528.
15. Ketelslegers IA, Visser IE, Neuteboom RF, et al. Disease course and outcome of acute
disseminated encephalomyelitis is more severe in adults than in children. Mult Scler 2011;
17:441.
16. Koelman DL, Chahin S, Mar SS, et al. Acute disseminated encephalomyelitis in 228 patients:
A retrospective, multicenter US study. Neurology 2016; 86:2085.
17. Noorbakhsh F, Johnson RT, Emery D, Power C. Acute disseminated encephalomyelitis:
clinical and pathogenesis features. Neurol Clin 2008; 26:759.

18. López-Chiriboga AS, Majed M, Fryer J, et al. Association of MOG-IgG Serostatus With
Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for
https://www.uptodate.com/contents/14087/print 21/33
3/30/23, 1:44 PM 14087

MOG-IgG-Associated Disorders. JAMA Neurol 2018; 75:1355.

19. Höllinger P, Sturzenegger M, Mathis J, et al. Acute disseminated encephalomyelitis in
adults: a reappraisal of clinical, CSF, EEG, and MRI findings. J Neurol 2002; 249:320.

20. Kaji M, Kusuhara T, Ayabe M, et al. Survey of herpes simplex virus infections of the central
nervous system, including acute disseminated encephalomyelitis, in the Kyushu and
Okinawa regions of Japan. Mult Scler 1996; 2:83.

21. Denes E, Magy L, Pradeau K, et al. Successful treatment of human herpesvirus 6

encephalomyelitis in immunocompetent patient. Emerg Infect Dis 2004; 10:729.
22. Silver B, McAvoy K, Mikesell S, Smith TW. Fulminating encephalopathy with perivenular
demyelination and vacuolar myelopathy as the initial presentation of human
immunodeficiency virus infection. Arch Neurol 1997; 54:647.
23. Tsiodras S, Kelesidis T, Kelesidis I, et al. Mycoplasma pneumoniae-associated myelitis: a
comprehensive review. Eur J Neurol 2006; 13:112.
24. Marchioni E, Ravaglia S, Piccolo G, et al. Postinfectious inflammatory disorders: subgroups
based on prospective follow-up. Neurology 2005; 65:1057.

25. Baxter R, Lewis E, Goddard K, et al. Acute Demyelinating Events Following Vaccines: A Case-
Centered Analysis. Clin Infect Dis 2016; 63:1456.
26. APPELBAUM E, NELSON J. Neurological complications following antirabies vaccination. J Am
Med Assoc 1953; 151:188.
27. Feery BJ. Adverse reactions after smallpox vaccination. Med J Aust 1977; 2:180.

28. Fenichel GM. Neurological complications of immunization. Ann Neurol 1982; 12:119.
29. Holt S, Hudgins D, Krishnan KR, Critchley EM. Diffuse myelitis associated with rubella
vaccination. Br Med J 1976; 2:1037.
30. Behan PO. Diffuse myelitis associated with rubella vaccination. Br Med J 1977; 1:166.
31. Honkaniemi J, Dastidar P, Kähärä V, Haapasalo H. Delayed MR imaging changes in acute
disseminated encephalomyelitis. AJNR Am J Neuroradiol 2001; 22:1117.

32. Marchioni E, Ravaglia S, Montomoli C, et al. Postinfectious neurologic syndromes: a

prospective cohort study. Neurology 2013; 80:882.
33. Kuperan S, Ostrow P, Landi MK, Bakshi R. Acute hemorrhagic leukoencephalitis vs ADEM:
FLAIR MRI and neuropathology findings. Neurology 2003; 60:721.
34. Atlas SW, Grossman RI, Goldberg HI, et al. MR diagnosis of acute disseminated
encephalomyelitis. J Comput Assist Tomogr 1986; 10:798.

https://www.uptodate.com/contents/14087/print 22/33
3/30/23, 1:44 PM 14087

35. Singh S, Alexander M, Korah IP. Acute disseminated encephalomyelitis: MR imaging

features. AJR Am J Roentgenol 1999; 173:1101.
36. Marin SE, Callen DJ. The magnetic resonance imaging appearance of monophasic acute
disseminated encephalomyelitis: an update post application of the 2007 consensus criteria.
Neuroimaging Clin N Am 2013; 23:245.
37. Mahdi N, Abdelmalik PA, Curtis M, Bar B. A Case of Acute Disseminated Encephalomyelitis
in a Middle-Aged Adult. Case Rep Neurol Med 2015; 2015:601706.

38. Balasubramanya KS, Kovoor JM, Jayakumar PN, et al. Diffusion-weighted imaging and
proton MR spectroscopy in the characterization of acute disseminated encephalomyelitis.
Neuroradiology 2007; 49:177.
39. Lakhan SE. Teaching neuroimages: MRI time lag with acute disseminated
encephalomyelitis. Neurology 2012; 78:e138.
40. Khurana DS, Melvin JJ, Kothare SV, et al. Acute disseminated encephalomyelitis in children:
discordant neurologic and neuroimaging abnormalities and response to plasmapheresis.
Pediatrics 2005; 116:431.
41. Pohl D, Alper G, Van Haren K, et al. Acute disseminated encephalomyelitis: Updates on an
inflammatory CNS syndrome. Neurology 2016; 87:S38.

42. Cole J, Evans E, Mwangi M, Mar S. Acute Disseminated Encephalomyelitis in Children: An

Updated Review Based on Current Diagnostic Criteria. Pediatr Neurol 2019; 100:26.
43. Papetti L, Figà Talamanca L, Spalice A, et al. Predictors of Evolution Into Multiple Sclerosis
After a First Acute Demyelinating Syndrome in Children and Adolescents. Front Neurol
2018; 9:1156.
44. Hennes EM, Baumann M, Schanda K, et al. Prognostic relevance of MOG antibodies in
children with an acquired demyelinating syndrome. Neurology 2017; 89:900.
45. Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: The history, clinical phenotype, and
pathogenicity of a serum biomarker for demyelination. Autoimmun Rev 2016; 15:307.
46. Krupp LB, Banwell B, Tenembaum S, International Pediatric MS Study Group. Consensus
definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007;
68:S7.
47. Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study
Group criteria for pediatric multiple sclerosis and immune-mediated central nervous
system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013; 19:1261.

48. Santoro JD, Chitnis T. Diagnostic Considerations in Acute Disseminated Encephalomyelitis

and the Interface with MOG Antibody. Neuropediatrics 2019; 50:273.

https://www.uptodate.com/contents/14087/print 23/33
3/30/23, 1:44 PM 14087

49. Keegan M, Pineda AA, McClelland RL, et al. Plasma exchange for severe attacks of CNS
demyelination: predictors of response. Neurology 2002; 58:143.
50. Marchioni E, Marinou-Aktipi K, Uggetti C, et al. Effectiveness of intravenous
immunoglobulin treatment in adult patients with steroid-resistant monophasic or
recurrent acute disseminated encephalomyelitis. J Neurol 2002; 249:100.
51. Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: Plasmapheresis in
neurologic disorders: report of the Therapeutics and Technology Assessment
Subcommittee of the American Academy of Neurology. Neurology 2011; 76:294.
52. Sekula RF Jr, Jannetta PJ, Rodrigues B, et al. Acute disseminated encephalomyelitis: a report
of two fulminant cases and review of literature. Neurol Neurochir Pol 2008; 42:458.

53. Ahmed AI, Eynon CA, Kinton L, et al. Decompressive craniectomy for acute disseminated
encephalomyelitis. Neurocrit Care 2010; 13:393.
54. Dombrowski KE, Mehta AI, Turner DA, McDonagh DL. Life-saving hemicraniectomy for
fulminant acute disseminated encephalomyelitis. Br J Neurosurg 2011; 25:249.
55. Lin CH, Jeng JS, Hsieh ST, et al. Acute disseminated encephalomyelitis: a follow-up study in
Taiwan. J Neurol Neurosurg Psychiatry 2007; 78:162.
56. Shah S, Shah D, Skeen MB. Recurrent disseminated encephalomyelitis: A case report and
literature review. Mult Scler Relat Disord 2018; 26:86.
57. Durston JH, Milnes JN. Relapsing encephalomyelitis. Brain 1970; 93:715.
Topic 14087 Version 19.0

https://www.uptodate.com/contents/14087/print 24/33
3/30/23, 1:44 PM 14087

GRAPHICS

Diagnostic criteria of acute disseminated encephalomyelitis (ADEM) in

children

Clinical features (all are required)

A first polyfocal, clinical central nervous system event with presumed inflammatory demyelinating
cause

Encephalopathy that cannot be explained by fever, systemic illness, or postictal symptoms

No new clinical and MRI findings emerge three months or more after the onset

Brain MRI is abnormal during the acute (three-month) phase

Lesion characteristics on brain MRI

Diffuse, poorly demarcated, large (>1 to 2 cm) lesions involving predominantly the cerebral white
matter

Deep gray matter lesions (eg, involving the basal ganglia or thalamus) can be present

T1 hypointense lesions in the white matter are rare

The clinical features of ADEM typically follow a monophasic disease course, although they can
fluctuate in severity and evolve in the first three months following disease onset. Multiphasic ADEM
is defined as two episodes consistent with ADEM separated by three months but not followed by any
further events. The second ADEM event can involve either new or a re-emergence of prior
neurologic symptoms, signs and MRI findings.

Adapted from: Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for
pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007
definitions. Mult Scler 2013; 19:1261.

Graphic 74896 Version 4.0

https://www.uptodate.com/contents/14087/print 25/33
3/30/23, 1:44 PM 14087

Acute hemorrhagic leukoencephalitis: MRI and

neuropathology findings

Representative axial T2-weighted (A), noncontrast T1-weighted (B),

postcontrast T1-weighted (C), and fast fluid-attenuated inversion
recovery (FLAIR) (D-F) 1.5-T MRI scans three days after neurologic
symptom onset. Images show bilateral confluent asymmetric lesions
in the posterior frontal, posterior temporal, parietal, and occipital
lobes, and splenium of the corpus callosum. Lesions extend from
the periventricular region to the subcortical white matter and gray-
white junction. Lesions are seen with comparable sensitivity on T2-
weighted vs FLAIR images and are mildly hypointense on T1-
weighted images without contrast enhancement. There was no
evidence of brain herniation or infratentorial lesions (not shown). (G)
This slide of deep white matter exhibits fine vacuolation
(arrowheads) due to edema, neutrophilic infiltrate (arrows), and a
cluster of extravasation of erythrocytes (upper left-middle of image,
thick arrows), all typical of acute hemorrhagic leukoencephalitis.
Myelin stains showed loss of myelin staining in the edematous areas

https://www.uptodate.com/contents/14087/print 26/33
3/30/23, 1:44 PM 14087

(not shown). There was no evidence of active infection. Hematoxylin

and eosin; original magnification ×400.

Reproduced with permission from: Kuperan S, Ostrow P, Landi MK, Bakshi R. Acute
hemorrhagic leukoencephalitis vs ADEM: FLAIR MRI and neuropathology findings.
Neurology 2003; 60:721. Copyright © 2003 American Academy of Neurology.
Unauthorized reproduction of this material is prohibited.

Graphic 89986 Version 8.0

https://www.uptodate.com/contents/14087/print 27/33
3/30/23, 1:44 PM 14087

Brain MRI of acute disseminated encephalomyelitis

(ADEM)

(A) Axial T2-weighted magnetic resonance imaging (MRI) showing

multiple, bilateral, hyperintense lesions in the periventricular white
matter.

(B) Axial T2-weighted MRI with extensive bihemispheric demyelinating

lesions involving the white matter and basal ganglia, extending into
the mesencephalon.

Reproduced with permission from: Menkes JH, Sarnat HB, Maria BL, Child Neurology,
7th Edition, Philadelphia, Lippincott Williams & Wilkins, 2006. Copyright © 2006
Lippincott Williams & Wilkins.

Graphic 89988 Version 1.0

https://www.uptodate.com/contents/14087/print 28/33
3/30/23, 1:44 PM 14087

Acute disseminated encephalomyelitis in a middle-aged

adult

https://www.uptodate.com/contents/14087/print 29/33
3/30/23, 1:44 PM 14087

MRI and brain biopsy findings in a 62-year-old man who initially presented
with progressive development of gait dysfunction, urinary incontinence, and
encephalopathy over the course of two weeks following four days of a
gastrointestinal illness.

(A) Axial (T2/FLAIR) MRI showing supratentoria white matter hyperintensities

extending from the periventricular region to the subcortical fibers.

(B) Sagittal (T2/FLAIR) MRI showing diffuse periventricular white matter

intensities.

(C) Axial (T2/FLAIR) MRI showing interval improvement and resolution of the
periventricular white matter lesions.

(D) Sagittal (T2/FLAIR) MRI demonstrating the improvement of the

periventricular white matter lesions.

(E) H&E stain shows areas of pallor containing macrophage that represent
areas of demyelination (original magnification 200x).

(F) Clusters of macrophages in the areas of demyelination are highlighted by

immunohistochemical staining for macrophage marker CD68 (original
magnification 200x).

(G) Relative preservation of axons that are seen to traverse the macrophage
rich areas of demyelination is demonstrated on neurofilament
immunohistochemical stain (original magnification 400x).

(H) Multiple pink areas of myelin loss are present in the background of normal
appearing blue staining cerebral white matter on Luxol Fast Blue/PAS stain
(original magnification 100x).

MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery;

H&E: hematoxylin and eosin; PAS: periodic acid-Schiff.

From: Mahdi N, Abdelmalik PA, Curtis M, Bar B. A case of acute disseminated encephalomyelitis
in a middle-aged adult. Case Rep Neurol Med 2015; 2015:601706. Copyright © 2015 Nicole
Mahdi et al. Available at: https://www.hindawi.com/journals/crinm/2015/601706/ (Accessed
February 15, 2017). Reproduced under the terms of the Creative Commons Attribution License.

Graphic 111832 Version 1.0

https://www.uptodate.com/contents/14087/print 30/33
3/30/23, 1:44 PM 14087

Neuromyelitis optica spectrum disorders diagnostic criteria for adult

patients

Diagnostic criteria for NMOSD with AQP4-IgG

1. At least one core clinical characteristic

2. Positive test for AQP4-IgG using best available detection method (cell-based assay strongly
recommended)

3. Exclusion of alternative diagnoses

Diagnostic criteria for NMOSD without AQP4-IgG or NMOSD with unknown AQP4-
IgG status
1. At least two core clinical characteristics occurring as a result of one or more clinical attacks and
meeting all of the following requirements:

a. At least one core clinical characteristic must be optic neuritis, acute myelitis with LETM, or
area postrema syndrome

b. Dissemination in space (two or more different core clinical characteristics)

c. Fulfillment of additional MRI requirements, as applicable

2. Negative tests for AQP4-IgG using best available detection method, or testing unavailable

3. Exclusion of alternative diagnoses

Core clinical characteristics

1. Optic neuritis

2. Acute myelitis

3. Area postrema syndrome: Episode of otherwise unexplained hiccups or nausea and vomiting

4. Acute brainstem syndrome

5. Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical

diencephalic MRI lesions

6. Symptomatic cerebral syndrome with NMOSD-typical brain lesions

Additional MRI requirements for NMOSD without AQP4-IgG and NMOSD with
unknown AQP4-IgG status
1. Acute optic neuritis: Requires brain MRI showing (a) normal findings or only nonspecific white
matter lesions, or (b) optic nerve MRI with T2-hyperintense lesion or T1-weighted gadolinium
enhancing lesion extending over more than one-half the optic nerve length or involving optic
chiasm

2. Acute myelitis: Requires associated intramedullary MRI lesion extending over ≥3 contiguous
segments (LETM) or ≥3 contiguous segments of focal spinal cord atrophy in patients with history
compatible with acute myelitis
https://www.uptodate.com/contents/14087/print 31/33
3/30/23, 1:44 PM 14087

3. Area postrema syndrome: Requires associated dorsal medulla/area postrema lesions

4. Acute brainstem syndrome: Requires associated periependymal brainstem lesions

AQP4: aquaporin-4; IgG: immunoglobulin G; LETM: longitudinally extensive transverse myelitis

lesions; NMOSD: neuromyelitis optica spectrum disorders.

From: Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica
spectrum disorders. Neurology 2015; 85:177. DOI: 10.1212/WNL.0000000000001729. Copyright © 2015 American Academy
of Neurology. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is
prohibited.

Graphic 102828 Version 3.0

https://www.uptodate.com/contents/14087/print 32/33
3/30/23, 1:44 PM 14087

Contributor Disclosures
Amy T Waldman, MD Grant/Research/Clinical Trial Support: Ionis Pharmaceuticals [Alexander disease];
Travere [Cerebrotendinous xanthomatosis]. All of the relevant financial relationships listed have been
mitigated. Francisco González-Scarano, MD Patent Holder: La Crosse [Monoclonal antibodies]. All of the
relevant financial relationships listed have been mitigated. Glenn A Tung, MD, FACR No relevant financial
relationship(s) with ineligible companies to disclose. John F Dashe, MD, PhD No relevant financial
relationship(s) with ineligible companies to disclose.

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are
addressed by vetting through a multi-level review process, and through requirements for references to be
provided to support the content. Appropriately referenced content is required of all authors and must
conform to UpToDate standards of evidence.

Conflict of interest policy

https://www.uptodate.com/contents/14087/print 33/33